Delin Ventures — 2022 Investments
4 investments dated 2022 · listed companies and verified rows first · show all
Immvention Therapeutics develops first-in-class BACH1 inhibitors intended as an oral therapy for patients with sickle cell disease and other conditions.
BiotechDigital HealthChapel Hill, US
Jenny Ting(Director and Co-founder)Matthew Cohen(Director)Lev Osherovich(Director)Mark Vellaca(Director)Anil Goyal(CEO and Director)
BoardBenjamin Scruggs(Director)
Co-investorsHatteras Venture PartnersOUP (Osage University Partners)
Ori develops expandable-unit technology for multifamily real estate, enabling hotel-to-housing conversions and ground-up developments that increase unit density while maintaining livability.
Construction TechHardwareImpact & Social GoodPropTech
Hasier Larrea(Founder)
Co-investorsIngka InvestmentsPresidio VenturesThe E14 FundAmadeus Capital PartnersEpisode1Khosla Ventures+4 more
ORI provides an integrated business planning platform for supply chain professionals, combining demand planning, S&OP, S&OE, data analytics, and long-term planning in one tool.
AI & Machine LearningLogistics & Supply ChainSaaS
Brant Slade(Founder)in
Co-investorsKickstartAmadeus Capital PartnersKhosla VenturesNorthpond VenturesNovalis LifeSciencesOctopus Ventures+2 more
Ori Biotech develops manufacturing automation platforms for cell and gene therapies, addressing scalability and cost barriers that limit patient access to these treatments.
Advanced ManufacturingBiotechDeep TechHardwareHealthtechMedical Devices
Co-investorsAmadeus Capital PartnersKindred CapitalNovalis LifeSciencesOctopus VenturesNorthpond VenturesPuhua Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.











